TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Financial Result For Quarter Ended 30Th June, 2023
Board has at its meeting held today approved, inter alia, the Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with limited review report of the Company for the quarter ended 30th June, 2023. The said financial results are enclosed herewith. TORRENT PHARMACEUTICALS LTD. - 500420 - Submission / Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - Financial Results For Quarter Ended 30Th June, 2023
Submission / Intimation u/r 30 of SEBI (LODR) Regulation, 2015 - Financial Result for quarter ended 30th June, 2023 TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Issue of Duplicate Share Certificates TORRENT PHARMACEUTICALS LTD. - 500420 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In furtherance to our earlier intimation dated 31st July, 2021, we wish to inform you that the National Company Law Tribunal, Mumbai vide its order dated 22nd June, 2023, the certified copy of which was received on 19th July, 2023, has approved the Scheme of Amalgamation for merger of Pharmasofttech Awacs Private Limited into Pharmarack Technologies Private Limited. Both these companies are subsidiaries of Aarogya Bharat Digital LLP (earlier known as DigiHealth Technologies LLP), which in turn is a wholly-owned subsidiary of ABCD Technologies LLP. The Company owns 6.45% interest ABCD Technologies LLP. The above is for your information and record. TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 7th August, 2023 at 06:00 P.M. to discuss the financial performance of the Company for the quarter ended 30th June, 2023. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith the copies of Newspaper cuttings published in Financial Express (English & Gujarati) on 15th July, 2023 in connection with the 50th Annual General Meeting and E-Voting Procedure. TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 ,inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on 30-Jun-23. TORRENT PHARMACEUTICALS LTD. - 500420 - Submission Of The Annual Report For The FY 2022-23 And The Notice Convening 50Th Annual General Meeting Of The Company.
Submission of the Annual Report for the FY 2022-23 and the notice convening 50th Annual General Meeting of the Company